ANÁLISIS RETROSPECTIVO DE LA EVOLUCIÓN CLÍNICA DE LOS PACIENTES CON LEUCEMIA LINFOCÍTICA CRÓNICA (LLC) TRATADOS CON VENETOCLAX EN LA PRÁCTICA REAL EN ESPAÑA (VENARES).

Datos básicos

Protocolo:
ABB-VEN-2019-01
EUDRACT:
NCT:
Centro:
HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
Año de incio:
2020
Año de finalización:
2021
ESTUDIO OBSERVACIONAL

Documentos

  • No hay documentos

Participantes

Grupos

Financiadores - Promotores

ABBVIE SPAIN SLU

Resultados del Ensayo Clínico


Accuracy and prognostic impact of FDG PET/CT and biopsyin bone marrow assessment of follicular lymphomaat diagnosis: A Nation-Wide cohort study.

Rodenas-Quinonero, Isabel; (...); Ortuno, Francisco Jose

Article. 10.1002/cam4.5424. 2022

  • Open Access.

Addition of chemotherapy to nivolumab after PD-1 inhibitor failure as bridge to allogeneic stem cell transplantation in classical Hodgkin's lymphoma: report on three cases and literature review

Romero, S; (...); Sanz, J

Review. 10.1177/20406207211038181. 2021

  • Open Access.

Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype

Ibanez, M; (...); Cervera, J

Article. 10.1038/s41598-020-61589-9. 2020

  • Open Access.

Assessment of the potential value of plasma Torque Teno virus DNA load monitoring to predict cytomegalovirus DNAemia in patients with hematological malignancies treated with small molecule inhibitors: A proof-of-concept study.

de la Asunción CS; (...); Navarro D

Article. 10.1002/jmv.28933. 2023

  • Open Access.

Central Nervous System Involvement in Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation.

Balaguer-Rosello, Aitana; (...); Sanz, Jaime

Article. 10.1016/j.jtct.2020.12.019. 2021

  • Open Access.

Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country.

Muntañola A; (...); Bosch F

Letter. 10.1186/s40164-020-00195-x. 2020

  • Open Access.

Cytomegalovirus-specific T-cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib.

Solano de la Asuncion, Carlos; (...); Navarro, David

Letter. 10.1111/bjh.17732. 2021

  • Open Access.

Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study

Ferra, Christelle; (...); Baltasar, Patricia

Meeting Abstract. 10.1182/blood-2022-162186. 2022

  • Open Access.

Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real World Setting in Spain: The Venares Study

Baltasar, Patricia; (...); Ferra, Christelle

Meeting Abstract. 10.1182/blood-2021-147685. 2021

  • Open Access.

Enhancing Cytogenetic Diagnostics: Incorporating Optical Genome Mapping in the Laboratory Routine

Diaz-Gonzalez, Alvaro; (...); Such, Esperanza

Meeting Abstract. 10.1182/blood-2023-180691. 2023

  • Open Access.

Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC).

Abrisqueta, Pau; (...); Bosch, Francesc

Article. 10.1016/j.eclinm.2024.102642. 2024

  • Open Access.

IBRUTINIB IN COMBINATION WITH R-GEMOX-D IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA IN RECALLING OR REFRACTORY: PHASE II STUDY OF THE GELTAMO GROUP

Rey, Bua Beatriz; (...); Martin, A.

Meeting Abstract. 2020

  • Open Access.

Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors.

de la Asuncion Carlos, Solano; (...); Navarro, David

Letter. 10.1111/bjh.18655. 2023

  • Open Access.

IMPACT OF ALLELIC STATUS OF TP53 MUTATIONS IN ACUTE MYELOID LEUKEMIA (AML)

Ibanez, Mariam; (...); Sanz, Guillermo

Meeting Abstract. 2020

  • Open Access.

Lineage switch from B lymphoblastic leukemia with KMT2A-rearranged to mixed-phenotype acute leukemia under daratumumab

Marco-Ayala, J; (...); Peris, MLS

Editorial Material. 10.5045/br.2020.2020059. 2020

  • Open Access.

Multi- Omics Exploration of Adaptive Mechanism to BTK Inhibition By Ibrutinib in CLL Identified TMBIM6/BI-1 As a Poor Prognosis Variable and Potential Therapeutic Target

Medina, Daniel; (...); Crespo, Marta

Meeting Abstract. 10.1182/blood-2023-185683. 2023

  • Open Access.

Panel Sequencing for Clinically Oriented Variant Screening and Copy Number Detection in Chronic Lymphocytic Leukemia Patients

Ibanez, Mariam; (...); Luna I

Article. 10.3390/diagnostics12040953. 2022

  • Open Access.

Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)

Abrisqueta, Pau; (...); Bosch, Francesc

Meeting Abstract. 10.1182/blood-2019-128470. 2019


RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group.

Bastos-Oreiro M; (...); López-Guillermo A

Article. 10.1007/s00277-020-03918-6. 2020


The Value of Bone Marrow Assessment by FDG PET/CT, Biopsy and Aspirate in the Upfront Evaluation of Mantle Cell Lymphoma: A Nationwide Cohort Study

Quinonero, Isabel Rodenas; (...); Ortuno, Francisco Jose

Article. 10.3390/cancers16244189. 2024

  • Open Access.

Updated Results of a Phase 2 Study from GELTAMO Investigating the Combination of Ibrutinib with R-GEMOX in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Bua, BR; (...); Garcia-Sancho, AM

Meeting Abstract. 2021


Campos de Estudio

Compartir